Spotlight on Family Medicine

Credits: 2.50 CME / CE
Addressing the Burden of Psoriatic Arthritis: Moving Beyond the Joint
Alexis R. Ogdie-Beatty, MD, MSCE
Annenberg Center for Health Sciences at Eisenhower

Addressing the Burden of Psoriatic Arthritis: Moving Beyond the Joint

Start

Activity Details

Free CME/AANP
2.5 AMA PRA Category 1 Credits
2.5 AANP Contact Hours
Released: January 31, 2020
Expires: January 30, 2021
2.5 hours to complete

Accredited By


Target Audience

This activity was developed for rheumatologists, dermatologists, primary care physicians, nurse practitioners, physician assistants, and other health care providers who manage patients with psoriatic arthritis (PsA).

Learning Objectives

  • Utilize validated tools to assess psoriatic arthritis (PsA) disease burden and response to treatment
  • Summarize the clinical pharmacology, including mechanism of action, as well as safety and efficacy, of evidence-based medications for PsA
  • Utilize a treat-to-target approach with individualized evidence-based therapy to reduce symptom burden and, when possible, achieve disease remission/low disease activity
  • Identify and implement treatment of comorbidities of PsA in collaboration with the primary care provider

Activity Description

Philip J. Mease, MD, and Alexis R. Ogdie-Beatty, MD, MSCE, review the pathogenesis and a wide spectrum of clinical features, manifestations, and comorbidities of psoriatic arthritis; talk about classification criteria for PsA and different patient-reported and provider-assessed outcome measures; and discuss treatment recommendations and strategies, as well as various types of current and emerging therapies. Finally, they highlight some of the key issues and challenges of the management of PsA through reviewing patient case studies.

Statement of Educational Need

According to the Rochester Epidemiology Project, 250,000 persons in the United States have psoriatic arthritis (PsA). An estimated 80% of patients with PsA suffer progressive joint damage despite the availability of safe, effective medications approved for PsA. As a consequence, patients with PsA generally experience impaired activities of daily living and patient function, health-related quality of life, and a substantial socioeconomic burden. Patients with PsA often experience difficulty bending down to pick up clothes from the floor (26%), dressing (15%), getting in and out of the car (15%), or bathing (12%). Fatigue and psychological morbidity are common as well. Despite experiencing substantial morbidity, many individuals with PsA view available treatment options as equally or more burdensome than the disease itself. Extra-articular complications are common and may affect lungs, heart, skin, eyes, and other organs; anemia is common as well.

The pharmacologic treatment of patients with PsA has evolved over the past decade. Several categories of medications are now approved, including oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitor, interleukin-17 inhibitors, cytotoxic T-lymphocyte-associated protein 4 immunoglobulin, and Janus kinase inhibitor. Within the past 2 years alone, abatacept, ixekizumab, and tofacitinib have been approved for PsA based on safety and efficacy results in phase 3 clinical trials.

Upon receiving a patient with possible PsA in referral, the specialist is tasked with confirming the diagnosis, followed by initiation of evidence-based therapy to induce remission and relieve patient morbidity. Doing so is often complicated by gaps in knowledge and competence.

Faculty

Alexis R. Ogdie-Beatty, MD, MSCE
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Penn Psoriatic Arthritis Clinic
University of Pennsylvania
Philadelphia, Pennsylvania


Philip J. Mease, MD
Clinical Professor of Medicine
University of Washington
Director
Rheumatology Research
Swedish Medical Center
Seattle, Washington

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.


In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Alexis R. Ogdie-Beatty, MD, MSCE

  • Consultant - AbbVie, Amgen, BMS, Celgene, Corona, Lilly, Novartis, Pfizer, UCB

Clinical area for disclosures above: Psoriatic Arthritis (PsA)

  • Other - Royalties from Novartis to spouse

Philip J. Mease, MD

  • Research Support - AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
    Consultant - AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB Speakers Bureau - AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB

Clinical area for disclosures above: Treatment of Rheumatic Disease

The faculty for this activity have disclosed that there will be discussion about the use of products for non–FDA approved indications.

Additional content planners
The following have no significant relationship to disclose:
Emir Hadzic, PhD (medical writer)
Kam A. Newman, MD (peer reviewer)

Annenberg Center for Health Sciences
Charles Willis, Director of Continuing Education, consults for Pfizer, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is accredited for 2.5 contact hours.
Program ID #5803-EM

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

Statement of Commercial Support

This activity is supported by an independent educational grant from Pfizer.

Contact Information for Questions about the Activity

For help or questions about this activity please contact Continuing Education: ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Activity Details

Free CME/AANP
2.5 AMA PRA Category 1 Credits
2.5 AANP Contact Hours
Released: January 31, 2020
Expires: January 30, 2021
2.5 hours to complete

Accredited By


Target Audience

This activity was developed for rheumatologists, dermatologists, primary care physicians, nurse practitioners, physician assistants, and other health care providers who manage patients with psoriatic arthritis (PsA).

Learning Objectives

  • Utilize validated tools to assess psoriatic arthritis (PsA) disease burden and response to treatment
  • Summarize the clinical pharmacology, including mechanism of action, as well as safety and efficacy, of evidence-based medications for PsA
  • Utilize a treat-to-target approach with individualized evidence-based therapy to reduce symptom burden and, when possible, achieve disease remission/low disease activity
  • Identify and implement treatment of comorbidities of PsA in collaboration with the primary care provider

Activity Description

Philip J. Mease, MD, and Alexis R. Ogdie-Beatty, MD, MSCE, review the pathogenesis and a wide spectrum of clinical features, manifestations, and comorbidities of psoriatic arthritis; talk about classification criteria for PsA and different patient-reported and provider-assessed outcome measures; and discuss treatment recommendations and strategies, as well as various types of current and emerging therapies. Finally, they highlight some of the key issues and challenges of the management of PsA through reviewing patient case studies.

Statement of Educational Need

According to the Rochester Epidemiology Project, 250,000 persons in the United States have psoriatic arthritis (PsA). An estimated 80% of patients with PsA suffer progressive joint damage despite the availability of safe, effective medications approved for PsA. As a consequence, patients with PsA generally experience impaired activities of daily living and patient function, health-related quality of life, and a substantial socioeconomic burden. Patients with PsA often experience difficulty bending down to pick up clothes from the floor (26%), dressing (15%), getting in and out of the car (15%), or bathing (12%). Fatigue and psychological morbidity are common as well. Despite experiencing substantial morbidity, many individuals with PsA view available treatment options as equally or more burdensome than the disease itself. Extra-articular complications are common and may affect lungs, heart, skin, eyes, and other organs; anemia is common as well.

The pharmacologic treatment of patients with PsA has evolved over the past decade. Several categories of medications are now approved, including oral small molecules, tumor necrosis factor inhibitors, interleukin-12/23 inhibitor, interleukin-17 inhibitors, cytotoxic T-lymphocyte-associated protein 4 immunoglobulin, and Janus kinase inhibitor. Within the past 2 years alone, abatacept, ixekizumab, and tofacitinib have been approved for PsA based on safety and efficacy results in phase 3 clinical trials.

Upon receiving a patient with possible PsA in referral, the specialist is tasked with confirming the diagnosis, followed by initiation of evidence-based therapy to induce remission and relieve patient morbidity. Doing so is often complicated by gaps in knowledge and competence.

Faculty

Alexis R. Ogdie-Beatty, MD, MSCE
Associate Professor of Medicine at the Hospital of the University of Pennsylvania
Director, Penn Psoriatic Arthritis Clinic
University of Pennsylvania
Philadelphia, Pennsylvania


Philip J. Mease, MD
Clinical Professor of Medicine
University of Washington
Director
Rheumatology Research
Swedish Medical Center
Seattle, Washington

Conflict of Interest Policy/Disclosure Statement

It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All faculty and planners participating in sponsored programs are expected to identify and reference off-label product use and disclose any relationship with those supporting the activity or any others with products or services available within the scope of the topic being discussed in the educational presentation.

The Annenberg Center for Health Sciences assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE/CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE/CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial interest.


In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:

Alexis R. Ogdie-Beatty, MD, MSCE

  • Consultant - AbbVie, Amgen, BMS, Celgene, Corona, Lilly, Novartis, Pfizer, UCB

Clinical area for disclosures above: Psoriatic Arthritis (PsA)

  • Other - Royalties from Novartis to spouse

Philip J. Mease, MD

  • Research Support - AbbVie, Amgen, Bristol Myers Squibb, Celgene, Janssen, Lilly, Novartis, Pfizer, Sun, UCB
    Consultant - AbbVie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Galapagos, Gilead, Janssen, Lilly, Novartis, Pfizer, Sun, UCB Speakers Bureau - AbbVie, Amgen, Bristol Myers Squibb, Celgene, Genentech, Janssen, Lilly, Novartis, Pfizer, UCB

Clinical area for disclosures above: Treatment of Rheumatic Disease

The faculty for this activity have disclosed that there will be discussion about the use of products for non–FDA approved indications.

Additional content planners
The following have no significant relationship to disclose:
Emir Hadzic, PhD (medical writer)
Kam A. Newman, MD (peer reviewer)

Annenberg Center for Health Sciences
Charles Willis, Director of Continuing Education, consults for Pfizer, Inc; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.

The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient’s unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

Accreditation Statement

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower is accredited by the American Association of Nurse Practitioners as an approved provider of nurse practitioner continuing education. Provider number: 040207.
This program is accredited for 2.5 contact hours.
Program ID #5803-EM

Instructions for Receiving Credit

This activity is an online enduring material. Successful completion is achieved by reading and/or viewing the materials, reflecting on its implications in your practice, and completing the assessment component.

Statement of Commercial Support

This activity is supported by an independent educational grant from Pfizer.

Contact Information for Questions about the Activity

For help or questions about this activity please contact Continuing Education: ce@annenberg.net
Annenberg Center for Health Sciences
39000 Bob Hope Drive
Dinah Shore Building
Rancho Mirage, CA 92270
Phone 760-773-4500
Fax 760-773-4513
8 AM – 5 PM, Pacific Time, Monday – Friday

Family Medicine Presentations

0.75 CME
Integrity Continuing Education, Inc.
Why Weight? The Family Practice Guide for Enhancing the Patient-Provider Connection in Obesity Management

Why Weight? The Family Practice Guide for Enhancing the Patient-Provider Connection in Obesity Management

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 31, 2020
Expires: July 31, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion​
  • Examine regional and ethnic disparities to tailor obesity interventions appropriately​
  • Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment​
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance

Activity Description

Obesity rates are increasing, and contrary to other major global risks, there is little evidence of successful population-level intervention strategies to reduce rates. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of clinicians. It is well known that there is a growing shortage of obesity specialists in the United States who diagnose and manage interrelated cardiometabolic diseases. Therefore, family practice physicians are expected to become the frontline providers to manage obesity in the near future.

A comprehensive, patient-centered approach to obesity improves patient outcomes, but rarely is implemented. In order for a patient-centered approach to be implemented, clinicians are required to know how to effectively engage their patients and be up-to-date on current medical anti-obesity therapies so they can select the most appropriate agent for their individual patient’s needs. This innovative activity will incorporate multiple evidence-based adult learning principles to improve family physicians' skills and confidence in weight-loss counseling and treatment.

Faculty

Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Gelesis, Medtronic, Novo Nordisk
Speakers’ BureausNovo Nordisk
Contracted Research: Novo Nordisk 

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2020 through July 31, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk, Inc.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 31, 2020
Expires: July 31, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for family practice and primary care providers involved in the management of patients with obesity.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Employ proven communication and counseling strategies to effectively engage patients in weight loss discussion​
  • Examine regional and ethnic disparities to tailor obesity interventions appropriately​
  • Incorporate current practice guidelines and quality indicators to optimize obesity screening, diagnosis, and treatment​
  • Evaluate the efficacy and safety of available and emerging pharmacologic therapies for weight loss and weight maintenance

Activity Description

Obesity rates are increasing, and contrary to other major global risks, there is little evidence of successful population-level intervention strategies to reduce rates. As with all chronic medical conditions, effective management of obesity must be based on a partnership between a highly motivated patient and a committed team of clinicians. It is well known that there is a growing shortage of obesity specialists in the United States who diagnose and manage interrelated cardiometabolic diseases. Therefore, family practice physicians are expected to become the frontline providers to manage obesity in the near future.

A comprehensive, patient-centered approach to obesity improves patient outcomes, but rarely is implemented. In order for a patient-centered approach to be implemented, clinicians are required to know how to effectively engage their patients and be up-to-date on current medical anti-obesity therapies so they can select the most appropriate agent for their individual patient’s needs. This innovative activity will incorporate multiple evidence-based adult learning principles to improve family physicians' skills and confidence in weight-loss counseling and treatment.

Faculty

Deborah Bade Horn, DO, MPH
Medical Director
Center for Obesity Medicine and Metabolic Performance
Clinical Assistant Professor
Department of Surgery
University of Texas McGovern Medical School
Houston, Texas


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Deborah Bade Horn, DO, MPH
Consulting Fees: Gelesis, Medtronic, Novo Nordisk
Speakers’ BureausNovo Nordisk
Contracted Research: Novo Nordisk 

Michelle R. Rizzo, ELS, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education (CME) for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 31, 2020 through July 31, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Disclaimer Statement/Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Novo Nordisk, Inc. do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Novo Nordisk, Inc.

1.00 CME
Academy for Continued Healthcare Learning
Revolutionizing T2T in RA: Future Paradigms with JAK Inhibitors

Revolutionizing T2T in RA: Future Paradigms with JAK Inhibitors

Start

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 24, 2020
Expires: July 24, 2021
60 minutes to complete

Accredited By

Target Audience

This activity is intended for rheumatologists, internal medicine specialists, nurses, and other allied health-care professionals, as well as patients and caregivers interested in treatment advances for rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess characteristics of patients with RA that may be predictive of poor response to biologic treatment and assess opportunities with novel therapies
  • Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule drugs for the treatment of RA
  • Implement treat-to-target strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors

Activity Description

How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms.

Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals.

Bonus supplemental material includes:

  • Understanding Discordance in RA Care
  • Patient Perspectives on Shared Decision-Making
  • What Patients with RA Want Their Rheumatologists to Know
  • EULAR 2020 RA Updates

Statement of Educational Need

Rheumatoid arthritis (RA) is a debilitating, inflammatory condition that has significant ramifications on a patient’s quality of life, risk for disability, morbidity, and mortality. The range of disease-modifying antirheumatic drugs (DMARDs) has shifted and expanded dramatically for RA over the last 20 years, facilitating the use of a treat-to-target approach. With multiple classes of biologic and targeted therapies now approved for RA and more biosimilars coming to market as patents expire on older biologic agents, therapy decisions are rapidly becoming more complex, and physicians may be struggling to keep up.

As the availability of these novel agents complicates treatment decisions for RA, physicians need to properly evaluate treat-to-target strategies for their patients and therapy selection that should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. In addition, rheumatologists and clinicians who treat or diagnose RA need to enhance their understanding of the latest treatments and best practices to manage their patient populations effectively. Physicians need to take an active approach to apply the current evidence in practice with their RA patients and alleviate the burden the patient faces.

Agenda

Clinical commentary highlights includes:

  • Available and emerging JAK inhibitors
  • Tactics for patients who may have a poor response to biologic treatment
  • Role and adverse event management of small molecule drugs 
  • The latest treat-to-target paradigms

Chair

Kevin Winthrop, MD, MPH
Professor,
Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Science University
Portland, OR


Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research Division
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA


William F.C. Rigby, MD
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH


Patient Ambassadors

Kelly O'Neill
Founder, Rheumatoid Arthritis Warrior Community
RAwarrior.com
Founder, Rheumatoid Patient Foundation


Shannon Young, EdD
Executive Director,
Rheumatoid Patient Foundation
rheum4us.org


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Kevin Winthrop, MD, MPH (Chair)
Sources of Funding for Research: Bristol Myers Squibb and Pfizer Inc.
Consulting Agreements: Abbvie, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Lilly, Pfizer Inc., Roche, UCB

Philip Mease, MD, MACR (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Bristol Myers Squibb, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Consulting Agreements: Abbvie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Speakers' Bureau: Abbvie, Amgen, Bristol Myers Squibb, Genentech, Janssen, Lilly, Novartis, Pfizer Inc., UCB

William F.C. Rigby, MD (Faculty)
Clinical Trials: Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.
Consulting Agreements (Occasional): Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use:
Baricitinib, filgotinib, upadacitinib as well as JAK inhibitors under investigation for RA

Patient Ambassador Disclosures

Kelly O'Neill and Shannon Young, EdD, have no financial relationships.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)

Instructions for Receiving Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org 

Activity Details

Free CME
1.0 AMA PRA Category 1 Credit(s)
Released: July 24, 2020
Expires: July 24, 2021
60 minutes to complete

Accredited By

Target Audience

This activity is intended for rheumatologists, internal medicine specialists, nurses, and other allied health-care professionals, as well as patients and caregivers interested in treatment advances for rheumatoid arthritis (RA).

Learning Objectives

Upon completion of this activity, participants will be able to:

  • Assess characteristics of patients with RA that may be predictive of poor response to biologic treatment and assess opportunities with novel therapies
  • Evaluate clinical efficacy, safety, and tolerability of biologic and small molecule drugs for the treatment of RA
  • Implement treat-to-target strategies for refractory patients considerate of disease activity, treatment response, and other patient-specific factors

Activity Description

How can clinicians be assured they have the most up-to-date information for improving their patients’ outcomes in RA care? In this clinical commentary, leading infectious disease expert Kevin Winthrop, MD, MPH, and Rheumatology experts Philip Mease, MD, MACR, and William F.C. Rigby, MD, discuss the latest evidence, safety data, and potential roles with the available and emerging JAK inhibitors, as well as current treat-to-target RA paradigms.

Because the patient plays such a critical role in shared decision-making, this activity will also include patient ambassadors sharing their perspectives, experiences, and treatment goals.

Bonus supplemental material includes:

  • Understanding Discordance in RA Care
  • Patient Perspectives on Shared Decision-Making
  • What Patients with RA Want Their Rheumatologists to Know
  • EULAR 2020 RA Updates

Statement of Educational Need

Rheumatoid arthritis (RA) is a debilitating, inflammatory condition that has significant ramifications on a patient’s quality of life, risk for disability, morbidity, and mortality. The range of disease-modifying antirheumatic drugs (DMARDs) has shifted and expanded dramatically for RA over the last 20 years, facilitating the use of a treat-to-target approach. With multiple classes of biologic and targeted therapies now approved for RA and more biosimilars coming to market as patents expire on older biologic agents, therapy decisions are rapidly becoming more complex, and physicians may be struggling to keep up.

As the availability of these novel agents complicates treatment decisions for RA, physicians need to properly evaluate treat-to-target strategies for their patients and therapy selection that should be made in concert with patients, after reviewing their treatment history, route of administration, and lifestyle preferences. In addition, rheumatologists and clinicians who treat or diagnose RA need to enhance their understanding of the latest treatments and best practices to manage their patient populations effectively. Physicians need to take an active approach to apply the current evidence in practice with their RA patients and alleviate the burden the patient faces.

Agenda

Clinical commentary highlights includes:

  • Available and emerging JAK inhibitors
  • Tactics for patients who may have a poor response to biologic treatment
  • Role and adverse event management of small molecule drugs 
  • The latest treat-to-target paradigms

Chair

Kevin Winthrop, MD, MPH
Professor,
Division of Infectious Diseases
Schools of Medicine and Public Health
Oregon Health and Science University
Portland, OR


Faculty

Philip Mease, MD, MACR
Director, Rheumatology Research Division
Swedish Medical Center/Providence-St. Joseph Health
Clinical Professor, University of Washington School of Medicine
Seattle, WA


William F.C. Rigby, MD
Professor of Medicine, Microbiology and Immunology
Division of Rheumatology
Vice Chairman, Academic Affairs
Department of Medicine
Dartmouth Medical School
Dartmouth-Hitchcock Medical Center
Lebanon, NH


Patient Ambassadors

Kelly O'Neill
Founder, Rheumatoid Arthritis Warrior Community
RAwarrior.com
Founder, Rheumatoid Patient Foundation


Shannon Young, EdD
Executive Director,
Rheumatoid Patient Foundation
rheum4us.org


Conflict of Interest Policy/Disclosure Statement

The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME activity.

The following financial relationships have been provided:

Kevin Winthrop, MD, MPH (Chair)
Sources of Funding for Research: Bristol Myers Squibb and Pfizer Inc.
Consulting Agreements: Abbvie, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Lilly, Pfizer Inc., Roche, UCB

Philip Mease, MD, MACR (Faculty)
Sources of Funding for Research: Abbvie, Amgen, Bristol Myers Squibb, Galapagos, Gilead Sciences, Inc., Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Consulting Agreements: Abbvie, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Galapagos, Gilead Sciences, Inc., GlaxoSmithKline, Janssen, Lilly, Novartis, Pfizer Inc., Sun Pharmaceutical Industries Ltd., UCB
Speakers' Bureau: Abbvie, Amgen, Bristol Myers Squibb, Genentech, Janssen, Lilly, Novartis, Pfizer Inc., UCB

William F.C. Rigby, MD (Faculty)
Clinical Trials: Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.
Consulting Agreements (Occasional): Abbvie, Bristol Myers Squibb, Gilead Sciences, Inc., Pfizer Inc.

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use:
Baricitinib, filgotinib, upadacitinib as well as JAK inhibitors under investigation for RA

Patient Ambassador Disclosures

Kelly O'Neill and Shannon Young, EdD, have no financial relationships.

Accreditation Statement

The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

(NOTE: Nurse practitioners may participate in this educational activity and earn a certificate of completion as AANP accepts AMA PRA Category 1 Credits™ through its reciprocity agreements.)

Instructions for Receiving Credit

This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

Statement of Commercial Support

Supported by an educational grant from Gilead Sciences, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

Contact Information for Questions About the Activity

For questions, contact Michelle Forcier at mforcier@achlcme.org 

0.25 CME / MOC
The France Foundation
Integrative Solutions to Challenges in Chronic Pain Management – Patient Case: Osteoarthritis (OA) of the Knee

Integrative Solutions to Challenges in Chronic Pain Management – Patient Case: Osteoarthritis (OA) of the Knee

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Released: July 22, 2020
Expires: July 21, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

  • Describe recent developments in the understanding of pain pathways/pain pathophysiology
  • Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
  • Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
  • Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

STEERING COMMITTEE
Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
  • Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.


Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
  • Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.


Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
  • Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

  • Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
    • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Released: July 22, 2020
Expires: July 21, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

  • Describe recent developments in the understanding of pain pathways/pain pathophysiology
  • Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
  • Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
  • Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will review and assess the interventions designed to improve the clinical outcomes of patients with chronic osteoarthritis (OA) pain.

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

STEERING COMMITTEE
Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
  • Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.


Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
  • Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.


Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
  • Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

  • Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
    • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.25 CME / MOC
The France Foundation
Integrative Solutions to Challenges in Chronic Pain Management – Applying Principles of Pain Management

Integrative Solutions to Challenges in Chronic Pain Management – Applying Principles of Pain Management

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Released: July 22, 2020
Expires: July 21, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

  • Describe recent developments in the understanding of pain pathways/pain pathophysiology
  • Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
  • Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
  • Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

STEERING COMMITTEE
Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
  • Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.


Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
  • Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.


Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
  • Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

  • Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
    • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
0.25 ABIM MOC point(s)
0.25 ABMS MOC point(s)
Released: July 22, 2020
Expires: July 21, 2021
15 minutes to complete

Accredited By

Target Audience

This activity is intended for physiatrists and PCPs, those in general internal medicine practices including NPs and PAs.

Learning Objectives

  • Describe recent developments in the understanding of pain pathways/pain pathophysiology
  • Summarize key points from widely accepted guidelines/standards of care on OA and chronic LBP
  • Formulate a plan for ongoing pain assessment that reflects current evidence and incorporates practical tools whenever feasible
  • Explain the implications of key efficacy and safety data on emerging treatment options for chronic pain due to OA and LBP

Activity Description

This activity will equip front-line clinicians with evidence-based knowledge and increased competence that can inform the assessment, management and referral of patients with chronic osteoarthritis (OA) pain and lower back pain (LBP).

Statement of Educational Need

There are a vast number of challenges in the proper differentiation, assessment, and management of chronic pain (specifically with osteoarthritis [OA] and low back pain [LBP]), and how key facets of pain pathways/pain pathophysiology can help to inform these assessments. There is a need to increase the knowledge and confidence of physiatrists and PCPs (including internal medicine, NP, and PAs) who manage these patients to know the advances in current and emerging management strategies, including the use of a multimodal approach to therapies. An emphasis for a greater integrated multidisciplinary approach for delivering quality coordinated care within and across settings together, in order to improve pain management and patient care in the community, is also needed.

Faculty

STEERING COMMITTEE
Robin Dore, MD
Clinical Professor of Medicine
Division of Rheumatology
David Geffen School of Medicine, UCLA
Los Angeles, CA
  • Robin Dore, MD, is a consultant for Amgen, Abbvie, Gilead, Lilly, Radius, and Sanofi. She is on a speaker’s bureau for Amgen, Abbvie, Lilly, Pfizer, Radius, UCB, and Sanofi. She has done research for Amgen, Abbvie, Biogen, Gilead, Lilly, and Pfizer.


Paul Doghramji, MD, FAAFP
Family Physician
Collegeville Family Practice
Medical Director of Health Services
Ursinus College
Collegeville, PA
  • Paul Doghramji, MD, FAAFP, has no relevant financial relationships to disclose.


Michael I. Danto, MD
Physical Medicine and Rehabilitation
Orthopaedic Specialty Institute
Orange County, CA
  • Michael I. Danto, MD, has no relevant financial relationships to disclose.

MOC REVIEWERS
Theodore Bruno, MD
Chief Medical Officer
The France Foundation

  • Theodore Bruno, MD, is a stock shareholder of Allergan. His spouse is an employee of Allergan.

Louis Kuritzky, MD
Family Medicine Residency Program
University of Florida Health

  • Louis Kuritzky, MD, is a consultant for Amgen, Allergan, Boehringer Ingelheim Pharmaceuticals, Inc, Lilly, Lundbeck, NovoNordisk, Sanofi, and Shire. In addition, he is on the speaker’s bureau for Amgen.

Conflict of Interest Policy/Disclosure Statement

In accordance with the ACCME Standards for Commercial Support, The France Foundation (TFF) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. TFF resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. Furthermore, TFF seeks to verify that all scientific research referred to, reported, or used in a CME/CE activity conforms to the generally accepted standards of experimental design, data collection, and analysis. TFF is committed to providing learners with high-quality CME/CE activities that promote improvements in health care and not those of a commercial interest.

Accreditation Statement

The France Foundation is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation of Credit

Physicians
The France Foundation designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

American Board of Internal Medicine (ABIM)
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.25 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Other American Board of Medical Specialties (ABMS) Member Boards
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Maintenance of Certification (“MOC”) Activities through the ABMS Continuing Certification Directory, “Integrative Solutions to Challenges in Chronic Pain Management” has met the requirements as a MOC Part II CME Activity (apply toward general CME requirement) for the following ABMS Member Boards:

MOC Part II CME Activity
Anesthesiology
Family Medicine
Physical Medicine and Rehabilitation
Psychiatry and Neurology
Radiology

Instructions for Receiving Credit

  • There are no fees for participating in and receiving credit for this activity.
  • Review the activity objectives and CME/CE information.
  • Complete the CME/CE activity
  • Complete the online posttest. A score of 100% is required to successfully complete this activity. The participant may take the test until successfully passed.
  • Complete the CME/CE evaluation/attestation form, which provides each participant with the opportunity to comment on how participating in the activity will affect their professional practice; the quality of the instructional process; the perception of enhanced professional effectiveness; the perception of commercial bias; and his/her views on future educational needs.
  • Credit documentation/reporting:
    • If you are requesting AMA PRA Category 1 Credits™ or a certificate of participation—your CME/CE certificate will be available for download.
    • If you are requesting ABIM MOC points, your MOC points will be submitted electronically to the ACCME, which will register data and notify certifying boards.
    • If you are requesting ABMS MOC points, please alert your board that you completed this activity.

Statement of Commercial Support

This program is supported by an independent education grant funded by Pfizer Inc, in partnership with Lilly USA, LLC.

Disclaimer Statement/Disclosure of Unlabeled Use

TFF requires CME faculty (speakers) to disclose when products or procedures being discussed are off label, unlabeled, experimental, and/or investigational, and any limitations on the information that is presented, such as data that are preliminary, or that represent ongoing research, interim analyses, and/or unsupported opinion. Faculty in this activity may discuss information about pharmaceutical agents that is outside of US Food and Drug Administration approved labeling. This information is intended solely for continuing medical education and is not intended to promote off-label use of these medications. TFF does not recommend the use of any agent outside of the labeled indications. If you have questions, contact the Medical Affairs Department of the manufacturer for the most recent prescribing information.

Contact Information for Questions About the Activity

If you have questions about this CME activity, please contact The France Foundation at 860-434-1650 or info@francefoundation.com.

0.75 CME
Integrity Continuing Education, Inc.
Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence

Advancing Diagnosis and Individualized Treatment of Severe Asthma Through Application of Guidelines and Latest Evidence

Start

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

Activity Details

Free CME
0.75 AMA PRA Category 1 Credit(s)
Released: July 22, 2020
Expires: July 22, 2021
45 minutes to complete

Accredited By

Target Audience

This educational initiative has been designed for allergists, pulmonologists, fellows, and internal medicine physicians involved in the management of patients with severe asthma.

Learning Objectives

  • Demonstrate the ability to diagnose patients with severe versus difficult-to-treat versus persistent uncontrolled asthma
  • Describe the risks of OCS overuse and summarize strategies to reduce OCS use in severe asthma
  • Employ biomarker testing in the evaluation of severe asthma and utilize results to classify patients with severe asthma
  • Develop personalized treatment plans for patients with severe asthma that are consistent with current evidence-based recommendations

Activity Description

Interactive Puzzle Activity

Statement of Educational Need

Severe asthma remains a disease with a high economic, healthcare, and patient burden. Patients with severe asthma suffer frequent exacerbations and the unpredictability of their disease. Prior to the availability of newer therapies that provide an opportunity to improve the management of patients with severe asthma, many patients relied on oral corticosteroids (OCS) as a mainstay of treatment. In fact, Cataldo et al. reported in 2020 that many patients with severe asthma were self-medicating with OCS during episodes of worsening symptoms or as prevention of such episodes in addition to physician-diagnosed exacerbation management. The utility of new therapies is underscored by the need for clinicians to be competent to make an efficient and accurate diagnosis and classification of severe asthma, to possess knowledge of recently released guidelines for severe asthma management, and to be able to select appropriate individualized therapy based on patient profiles and desires. This program has been designed to ensure that fellows and post-specialty-trained clinicians are able to meet the needs of the diverse population of severe asthma patients and design effective treatment plans to reduce symptoms, exacerbations, and the continued need for OCS in patients with severe asthma. 

Faculty

Reynold A. Panettieri, Jr., MD
Professor of Medicine
Robert Wood Johnson Medical School
Vice Chancellor, Clinical & Translational Science
Director, Rutgers Institute for Translational Medicine & Science
New Brunswick, New Jersey
Emeritus Professor of Medicine
University of Pennsylvania
Philadelphia, Pennsylvania


Conflict of Interest Policy/Disclosure Statement

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Reynold A. Panettieri, Jr., MD​
Consulting Fees: AstraZeneca, MedImmune, RIFM, Equillium, Theravance
Speakers’ Bureaus: AstraZeneca, Sanofi, Genentech
Contracted Research: AstraZeneca, MedImmune, RIFM, Genentech, OncoArendi

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

Integrity Continuing Education, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Instructions for Receiving Credit

There are no fees for participating and receiving CME credit for this activity. During the period of July 22, 2020 through July 22, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and Sanofi Genzyme and Regeneron Pharmaceuticals do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

Contact Information for Questions About the Activity

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or info@integrityce.com.

Statement of Commercial Support

Supported by an educational grant from Sanofi Genzyme and Regeneron Pharmaceuticals.

0.25 CME
Medical Education Resources (MER)
Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Exploring the Advantages of Early Treatment for Diabetic Eye Disease

Bridging the Gap Between Diabetic Primary Care and Retinal Specialty Practice - Exploring the Advantages of Early Treatment for Diabetic Eye Disease

Start

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 15, 2020
Expires: July 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™, Medical Education Resources, and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Strategies for improved patient care
  • Differences between proliferative diabetic retinopathy (PDR) and nonproliferative diabetic retinopathy (NPDR)
  • Evolution of the nonproliferative diabetic retinopathy classifications systems
  • Progression of nonproliferative diabetic retinopathy to sight-threatening DR and blindness
  • Potential benefits of treating patients who have NPDR

Faculty

Rishi P. Singh, MD
Staff Surgeon
Cole Eye Institute
Cleveland Clinic
Associate Professor of Ophthalmology
Lerner College of Medicine
Cleveland, OH


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funded by Apellis and Graybug. Additionally, he has received consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

Activity Details

Free CME
0.25 AMA PRA Category 1 Credit(s)
Released: July 15, 2020
Expires: July 15, 2021
15 minutes to complete

Accredited By

Jointly Provided By

Creative Services Provided By

Target Audience

Primary Care Physicians

Learning Objectives

Describe the unmet need for diabetic eye care and the risks associated with delayed intervention.

Activity Description

Infinity Medical Education™, Medical Education Resources, and infograph-ed™ have created a highly engaging, interactive learning experience. A series of three modular infographics will build on each other. The goal of this activity is to educate primary care clinicians on the most critical needs in diabetic care that are not being regularly met. Namely, patients are missing annual diabetic eye exams and are losing vision as a result. Primary care physicians are at the front line of diabetic care, directing patients through their healthcare journey, and these clinicians provide an essential touchpoint at which patients with diabetes can and should be directed to eye care providers.

Statement of Educational Need

Diabetes is a growing health crisis and primary care physicians are at the front line, directing patients through several other steps along their healthcare journey. Unfortunately, one of the most critical needs in diabetic care is not regularly met. Specifically, patients are missing annual diabetic eye exams and are losing vision as a result. Countless patients go blind because they either never enter the treatment continuum or they miss follow-up appointments. This comes at a time when retinal specialists are calling for treatment at earlier stages of disease.

The primary care visit is an essential touchpoint at which patients with diabetes can and should be directed to eye care providers who can deliver much-needed diagnostic services and treatments. This interactive learning opportunity will engage physicians and inspire a more proactive approach to patient education. Physicians will learn the unmet need for diabetic eye care and the risks associated with delayed intervention. Additionally, they will become well-acquainted with the science behind vision-saving treatments for patients with diabetic macular edema and diabetic retinopathy. Furthermore, this program will emphasize the potential advantages of moving patients into treatment sooner rather than later.

Topics

  • Strategies for improved patient care
  • Differences between proliferative diabetic retinopathy (PDR) and nonproliferative diabetic retinopathy (NPDR)
  • Evolution of the nonproliferative diabetic retinopathy classifications systems
  • Progression of nonproliferative diabetic retinopathy to sight-threatening DR and blindness
  • Potential benefits of treating patients who have NPDR

Faculty

Rishi P. Singh, MD
Staff Surgeon
Cole Eye Institute
Cleveland Clinic
Associate Professor of Ophthalmology
Lerner College of Medicine
Cleveland, OH


Conflict of Interest Policy/Disclosure Statement

Medical Education Resources (MER) and Infinity Medical Education require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to MER policy. MER is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Rishi P. Singh, MD, has disclosed grant research funded by Apellis and Graybug. Additionally, he has received consulting fees from Genentech, Regeneron, Zeiss, Optos, Bausch and Lomb, Novartis and Alcon. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her/his presentation.

Medical Education Resources’ planners and managers have disclosed no relevant financial relationships.

The employees of Infinity Medical Education, LLC have disclosed no relevant financial relationships.

Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Education Resources (MER) and Infinity Medical Education. MER is accredited by the ACCME to provide continuing medical education for physicians.

Designation of Credit

Medical Education Resources designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions for Receiving Credit

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 66% or better.

Statement of Commercial Support

This continuing medical education activity is supported through an unrestricted educational grant from Regeneron Pharmaceuticals.

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

Medical Education Resources
http://cmepartner.org/contact or call toll-free: 800-421-3756

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Treating Flu in a 69-year-old Patient With COPD

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Treating Flu in a 69-year-old Patient With COPD
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Managing Flu in an Immunocompromised Patient

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: Managing Flu in an Immunocompromised Patient

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Managing Flu in an Immunocompromised Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA, FACP

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: Managing Flu in an Immunocompromised Patient
Paul G. Auwaerter, MD, MBA, FIDSA and Roy F. Chemaly, MD, MPH, FIDSA, FACP

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

0.25 CME / MOC
Vindico
Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu

Influenza: Reducing Complications in High-Risk Patients Through Advanced Treatment Options – Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu

Start

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
0.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
0.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Curbside Consult: An Adult Patient With Asthma and Symptoms of Flu
Paul G. Auwaerter, MD, MBA, FIDSA and John J. Russell, MD

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 0.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 100% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

1.25 CME / MOC
Vindico
Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases

Reducing Influenza Complications in High-Risk Patients: A Virtual Symposium With Challenging Clinical Cases

Start

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Activity Details

Free CME/MOC
1.25 AMA PRA Category 1 Credit(s)
/ABIM MOC
Released: June 29, 2020
Expires: June 28, 2021
1.25 hours to complete

Accredited By

This continuing medical education activity is provided by

Target Audience

The intended audience for the activity is allergists, immunologists, family practice physicians, general practice physicians, internists, pulmonologists, nurse practitioners, physician assistants, and other health care professionals involved in the management of patients with influenza.

Learning Objectives

Upon successful completion of the activity, participants should be better able to: 

  • Incorporate revised guidelines into practice to improve earlier detection and treatment of patients with influenza and comorbid respiratory conditions.
  • Compare influenza antiviral treatments in terms of their efficacy, safety, and ability to reduce viral shedding and infection in others.
  • Incorporate the most appropriate therapeutic regimen in patients with influenza who are at high risk for complications.

Activity Description

In this educational program, expert faculty will discuss strategies for incorporating the latest information regarding the diagnosis and treatment of influenza into practice. Using challenging case-based examples, faculty will provide guidance on selecting the most appropriate therapeutic regimen to reduce morbidity and mortality in patients with influenza who are at high risk for complications.

Faculty

Activity Chair:
Paul G. Auwaerter, MD, MBA, FIDSA
Sherrilyn and Ken Fisher Professor of Medicine
Clinical Director, Division of Infectious Diseases
Director, Sherrilyn and Ken Fisher Center for Environmental Infectious Diseases
Johns Hopkins University School of Medicine
Baltimore, MD
  • Disclosure:
  • Consulting Fee: Advanced Biotherapeutics, DiaSorin
  • Ownership Interest: Johnson & Johnson


Faculty:
Roy F. Chemaly, MD, MPH, FIDSA, FACP
Professor of Medicine
Director, Clinical Virology Research
Director, Infection Control Section
Department of Infectious Diseases/Infection Control, and Employee Health
University of Texas MD Anderson Cancer Center
Houston, TX
  • Disclosure:
  • Consulting Fee: ADMA Biologics, Ansun BioPharma, Chimerix, Genentech, Janssen, Kyorin, Partner Therapeutics, Pulmotect, ReViral, Symbio
  • Speakers Bureau: Merck, Oxford Immunotec, Xenex
  • Contracted Research: Ansun, Chimerix, Gilead, Karius, Merck, Novartis, Oxford Immunotec, Shire/Takeda, Xenex, Viracor
  • Ownership Interest: Xenex


John J. Russell, MD
Clinical Professor of Family and Community Medicine
Thomas Jefferson University
Sidney Kimmel School of Medicine
Philadelphia, PA
Chair, Department of Family Medicine
Program Director, Family Medicine Residency
Abington – Jefferson Health
Abington, PA
  • Disclosure:
  • Consulting Fee: GlaxoSmithKline, Sanofi Pasteur
  • Speakers Bureau: Sanofi Pasteur


Reviewers:
Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
Disclosure: No relevant financial relationships to disclose.

Ronald A. Codario, Jr., MD
Disclosure: No relevant financial relationships to disclose.

Vindico Medical Education Staff:
Disclosure: No relevant financial relationships to disclose. 

Signed Disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Agenda

Introduction
Paul G. Auwaerter, MD, MBA, FIDSA

Influenza Management: What’s New in 2020?
Paul G. Auwaerter, MD, MBA, FIDSA

Challenging Case 1: Diagnosing and Treating Flu in the Nursing Home Patient With COPD
John J. Russell, MD

Challenging Case 2: The Pediatric Asthmatic Patient With Symptoms of Flu
John J. Russell, MD

Challenging Case 3: Managing Flu in an Immunocompromised Patient
Roy F. Chemaly, MD, MPH, FIDSA, FACP

Key Takeaways and Conclusion
Paul G. Auwaerter, MD, MBA, FIDSA

Conflict of Interest Policy/Disclosure Statement

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears above.

Accreditation Statement

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Designation of Credit

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity enables the participant to earn up to 1.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants who opt-in will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC points.

Nurse practitioners can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Nurse Practitioners Certification Board (AANPCB). AANPCB will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by Accreditation Council for Continuing Medical Education.

Physician assistants participating in the enduring activity can apply for AMA PRA Category 1 Credit(s)™ through the American Academy of Physician Assistants (AAPA). AAPA will accept AMA PRA Category 1 Credit(s)™ from organizations accredited by the ACCME.

Instructions for Receiving Credit

To participate in this CME activity, you must read the objectives, answer the pretest questions, view the CME content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 75% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.

Statement of Commercial Support

This activity is supported by an educational grant from Genentech, Inc.

Disclaimer Statement/Disclosure of Unlabeled Use

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non‒FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447.Telephone: 856-994-9400;Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at CME@VindicoCME.com

Pages